製品番号: HY-N0444

Rubiadin

(別名: ルビアジン)

カスタマーレビュー

Based on 1 Customer Validation

Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.20%
CAS 番号: 117-02-2
分子式: C₁₅H₁₀O₄
分子量:254.24

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Rubiadin 構造式

CAS 番号: 117-02-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

NF-κB アイソフォーム固有の製品をすべて表示 :

Parasite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	32 μM Compound: 10, rubiadin	Cytotoxicity against Homo sapiens (human) DU145 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) DU145 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5
MCF7	IC₅₀	56 μM Compound: 10, rubiadin	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5
MES-SA	IC₅₀	38 μM Compound: 10, rubiadin	Cytotoxicity against Homo sapiens (human) MES-SA cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MES-SA cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5
MES-SA/Dx5	IC₅₀	35 μM Compound: 10, rubiadin	Cytotoxicity against Homo sapiens (human) MES-SA/Dx5 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MES-SA/Dx5 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5
NCI-H460	IC₅₀	42 μM Compound: 10, rubiadin	Cytotoxicity against Homo sapiens (human) H460 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) H460 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5

体外実験

Rubiadin (5-20 μM; 3 h pre-incubation, then 24 h continued incubation) protects N2a cells against Aβ1₋42-induced cytotoxicity, significantly enhancing cell viability relative to Aβ1₋42-only treated cells^[4].
Rubiadin (5-20 μM; 3 h pre-incubation, then 24 h continued incubation) suppresses activation of the IKK/IκB/NF-κB pathway in Aβ_1-42-induced N2a cells by reducing phosphorylation of key pathway components^[4].
Rubiadin (1-100 μM; 24 h post-irradiation) induces light dose-dependent cytotoxicity in MCF-7c3 human breast cancer cells, with an LD₅₀ of 0.66 J/cm², reducing viability by 76% at 100 μM and 1 J/cm²^[5].
Rubiadin (0.4-40 μM; 24 h) does not impair the viability of human HepG2 cells^[6].
Rubiadin (0.4-40 μM; 24 h, dose-dependent) and (20 μM; 3-24 h, time-dependent) upregulates hepcidin mRNA and protein expression in human HepG2 cells in both a dose-dependent and time-dependent manner, with maximal 5-fold mRNA upregulation at 20 μM for 24 h^[6].
Rubiadin (5, 10, 20, 40 μg/ml; 72 h) dose-dependently inhibits the proliferation of HepG2.2.15 cells with an IC₅₀ of 17 μg/ml, and nontoxic concentrations (<8 μg/ml) support its use in anti-HBV activity assays^[7].
Rubiadin (4, 6 μg/ml; 24, 48, 72 h) dose-dependently reduces the secretion of HBsAg, HBeAg, and HBcAg by HepG2.2.15 cells, with particularly potent inhibition of HBeAg and HBcAg at 72 h^[7].
Rubiadin inhibits Candida tropicalis biofilm formation and induces oxidative stress under irradiation, and acts synergistically with Amphotericin B against the fungus^[8].
Rubiadin inhibits Plasmodium falciparum viability with an IC₅₀ of 13.00 μg/mL, reducing schizont counts in a dose-dependent manner^[8].
Rubiadin exhibits moderate experimental DPPH radical scavenging activity in aqueous physiological media (pH 7.4), with an IC₅₀ of 91.00 μM^[9].
Rubiadin exhibits moderate experimental ABTS^•+ radical scavenging activity in aqueous physiological media (pH 7.4), with an IC₅₀ of 73.44 μM^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

mouse neuroblastoma N2a cells (Aβ1₋42-induced model)
Concentration:

5 μM; 20 μM
Incubation Time:

3 h pre-incubation, then 24 h continued incubation
Result:

Significantly improved cell viability in Aβ1₋42-exposed N2a cells.

Western Blot Analysis^[4]

Cell Line:

mouse neuroblastoma N2a cells (Aβ1₋42-induced model)
Concentration:

5 μM; 20 μM
Incubation Time:

3 h pre-incubation, then 24 h continued incubation
Result:

Reduced the expression levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α. Increased the expression of anti-inflammatory cytokine IL-4. Decreased phosphorylated Tau protein expression in Aβ1₋42-exposed N2a cells.\nSignificantly inhibited the phosphorylation of IKK, IκB, and NF-κB in Aβ1₋42-exposed N2a cells.

Immunofluorescence^[4]

Cell Line:

mouse neuroblastoma N2a cells (Aβ1₋42-induced model)
Concentration:

5 μM; 20 μM
Incubation Time:

3 h pre-incubation, then 24 h continued incubation
Result:

Reversed the increased nuclear overlap of NF-κB and DAPI-labeled nuclei observed in Aβ1₋42-exposed N2a cells. Significantly reduced NF-κB nuclear fluorescence intensity.

Cell Cytotoxicity Assay^[5]

Cell Line:

MCF-7c3 human breast cancer cells
Concentration:

1, 50, 100 μM
Incubation Time:

24 h (post-irradiation)
Result:

Exhibited photochemical activity in a light dose-dependent manner, with an LD50 value at 0.66 J/cm2 light dose and 76% cell killing at 1 J/cm2.

Western Blot Analysis^[6]

Cell Line:

human HepG2 cells, ferric ammonium citrate (FAC)-treated human HepG2 cells
Concentration:

0.4, 4, 8, 20, 40 μM (untreated cells); 20 μM (FAC-pretreated cells)
Incubation Time:

24 h (untreated cells); 24 h (FAC-pretreated cells)
Result:

Dose-dependently decreased protein expression of TfR1, Fpn1 and FtL in untreated HepG2 cells, with significant reductions at 20 and 40 μM for TfR1 and Fpn1, and at 8, 20, and 40 μM for FtL; had no significant effect on divalen DMT1 or FtH expression.\nFurther decreased TfR1 protein expression and reversed FAC-induced elevation of FtL protein expression in FAC-pretreated HepG2 cells; had no significant effect on Fpn1, DMT1, or FtH expression in FAC-pretreated cells.

ELISA Assay^[7]

Cell Line:

HepG2.2.15 human hepatoma cells
Concentration:

4, 6 μg/ml
Incubation Time:

24, 48, 72 h
Result:

Dose-dependently decreased extracellular levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antigen (HBcAg). Reduced HBeAg secretion by 26.31% and HBcAg secretion by 29.26% at 72 h, with more efficient inhibition than the positive control.

Cell Cycle Analysis^[7]

Cell Line:

HepG2.2.15 human hepatoma cells
Concentration:

4, 6 μg/ml
Incubation Time:

72 h
Result:

Resulted in G0/G1 phase percentages of 75.2% (4 μg/ml) and 78.1% (6 μg/ml), with no statistically significant difference from the untreated control (73.3%). Induced no cell cycle arrest.

体内実験

Rubiadin (0.3-0.5 mg/kg; i.p.; single dose) exhibits significant acute anti-inflammatory activity, with a 61% inhibition of peak carrageenan-induced paw edema and a significant reduction in paw tissue TNF-α levels in male Wistar albino rats^[2].
Rubiadin (50-200 mg/kg; p.o.; daily; 14 days) exhibits dose-dependent hepatoprotective activity against CCl₄-induced hepatic damage in Sprague-Dawley rats, with highly significant efficacy at 100 and 200 mg/kg that approaches the activity of the reference drug silymarin^[3].
Rubiadin (20 mg/kg; intragastric; daily; 8 weeks) improves spatial and non-spatial memory, reduces cerebral Aβ deposition, mitigates neuroinflammation, and inhibits NF-κB pathway activation in APP/PS1 Alzheimer's disease model mice^[4].
Rubiadin (1 mg/kg; i.p.; every other day; 6 weeks) reduces serum iron, total iron-binding capacity, and transferrin saturation in normal 8-week-old C57BL/6 male mice^[6].
Rubiadin (5-20 mg/kg; i.p.; daily; 4 weeks) alleviates iron overload in high-iron diet-fed C57BL/6 male mice by reversing splenomegaly, reducing serum iron parameters and duodenal iron content, and enhancing hepatic hepcidin expression and SMAD1/5/9 phosphorylation^[6].
Rubiadin (100-250 mg/kg; p.o.; daily; 3 days) exhibits anticonvulsant effects in Swiss albino mice, reducing seizure severity in both pentylene tetrazole and maximal electro shock models when administered orally at 100 and 250 mg/kg for 3 days^[8].
Rubiadin (0.04%; dietary; daily; 23 weeks) acts as a carcinogenic metabolite in F344 rats, enhancing renal preneoplastic lesions, liver cell foci, and intestinal dysplasias when administered at 0.04% in the diet for 23 weeks^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar albino rats (male, 150-200 g)^[2]
Dosage:

0.3 mg/kg; 0.5 mg/kg
Administration:

i.p.; single dose
Result:

Produced paw edema inhibition percentages of 24% (0.5 hr), 17.5% (1 hr), 8.3% (2 hr), 21% (3 hr), and 13% (4 hr) at 0.3 mg/kg.\nProduced paw edema inhibition percentages of 48% (0.5 hr), 40% (1 hr), 45% (2 hr), 61% (3 hr), and 54% (4 hr) at 0.5 mg/kg, with 61% inhibition at peak edema time being statistically significant.\nCaused a statistically significant decrease in paw tissue TNF-α levels at 0.5 mg/kg compared to controls.\nSignificantly reduced paw tissue edema and histopathological damage compared to controls at both doses.

Animal Model:

Wistar albino rats (male, 150-200 g)^[2]
Dosage:

0.3 mg/kg; 0.5 mg/kg
Administration:

i.p.; daily; 7 days
Result:

Produced 34.71% inhibition of granuloma formation and 19.76% inhibition of transudate formation at 0.3 mg/kg.\nProduced 46.12% inhibition of granuloma formation and 38.13% inhibition of transudate formation at 0.5 mg/kg, with both values statistically. Caused a statistically significant decrease in serum IL-1β levels at 0.5 mg/kg compared to controls.

Animal Model:

C57BL/6 (6-week-old, male; high-iron diet-induced iron overload)^[6]
Dosage:

5 mg/kg; 20 mg/kg
Administration:

i.p.; daily; 4 weeks
Result:

Did not significantly affect mouse body weight.\nSignificantly reversed splenomegaly, reduced elevated serum iron, total iron-binding capacity, and transferrin saturation caused by the high-iron diet, and reversed the elevated duodenal iron content caused by the high-iron diet.\nFurther increased hepatic hepcidin mRNA expression, hepatic hepcidin protein expression, and hepatic SMAD1/5/9 phosphorylation levels relative to the high-iron diet alone.

Animal Model:

Wistar (carbon tetrachloride-induced liver injury)^[8]
Dosage:

50 mg/kg; 100 mg/kg; 200 mg/kg
Administration:

p.o.; daily; 2 weeks
Result:

Restored serum glutamic oxaloacetic transaminase, glutamate pyruvate transaminase, alkaline phosphatase, γ-glutamyltransferase, glutathione S-transferase, and glutathione reductase levels to normal.\nInhibited hepatic malondialdehyde formation in a dose-dependent manner.\nReduced glutathione depletion in a dose-dependent manner.

Animal Model:

Wistar (streptozotocin-nicotinamide-induced diabetic nephropathy)^[8]
Dosage:

100 mg/kg/week; 200 mg/kg/week
Administration:

p.o.
Result:

Markedly reduced blood glucose levels, urea, uric acid, and creatinine levels.\nImproved lipid, thiobarbituric acid reactive substances, glutathione, superoxide dismutase, and catalase levels.

Animal Model:

F344^[8]
Dosage:

0.04%
Administration:

dietary; daily; 23 weeks
Result:

Enhanced atypical renal tubules/hyperplasias.\nInduced renal cell adenomas and carcinomas.\nIncreased glutathione S-transferase placental form-positive liver cell foci.\nCaused major intestinal dysplasias.

化学情報

CAS 番号 117-02-2
性状 Solid
分子量 254.24
分子式 C₁₅H₁₀O₄
Color Light yellow to yellow
SMILES

O=C1C2=C(C=CC=C2)C(C3=CC(O)=C(C)C(O)=C13)=O
別名

ルビアジン
Structure Classification
- Quinones
- Anthraquinones
- Phenols
- Polyphenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : ≥ 6.25 mg/mL (24.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9333 mL

19.6665 mL

39.3329 mL

5 mM

0.7867 mL

3.9333 mL

7.8666 mL

10 mM

0.3933 mL

1.9666 mL

3.9333 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (295 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Hui Huang, et al. Rubiadin Regulates Bone Metabolism in Ovariectomized Rat Model by Inhibition of osteoclast formation and differentiation. ChemistrySelect 2023, 8, e202300115 (1 of 11).

[2]. Chitsaz R, et al. Rubiadin exerts an acute and chronic anti-inflammatory effect in rodents. Braz J Biol. 2021;83:e243775. Published 2021 Dec 13. [Content Brief]

[3]. Rao GM, et al. Hepatoprotective effects of rubiadin, a major constituent of Rubia cordifolia Linn. J Ethnopharmacol. 2006;103(3):484-490. [Content Brief]

[4]. Zhang Y, et al. Rubiadin Alleviates Alzheimer's Disease Pathology via NF-κB Pathway Regulation. J Integr Neurosci. 2025;24(10):33497. [Content Brief]

[5]. Rumie Vittar NB, et al. Photochemotherapy using natural anthraquinones: Rubiadin and Soranjidiol sensitize human cancer cell to die by apoptosis. Photodiagnosis Photodyn Ther. 2014;11(2):182-192. [Content Brief]

[6]. Xie X, et al. Rubiadin Mediates the Upregulation of Hepatic Hepcidin and Alleviates Iron Overload via BMP6/SMAD1/5/9-Signaling Pathway. Int J Mol Sci. 2025;26(3):1385. Published 2025 Feb 6. [Content Brief]

[7]. Peng Z, et al. Effects of Rubiadin isolated from Prismatomeris connata on anti-hepatitis B virus activity in vitro. Phytother Res. 2017;31(12):1962-1970. [Content Brief]

[8]. Watroly MN, et al. Chemistry, Biosynthesis, Physicochemical and Biological Properties of Rubiadin: A Promising Natural Anthraquinone for New Drug Discovery and Development. Drug Des Devel Ther. 2021;15:4527-4549. Published 2021 Nov 3. [Content Brief]

[9]. Hieu LT, et al. The Theoretical and Experimental Insights into the Radical Scavenging Activity of Rubiadin. J Phys Chem B. 2023;127(51):11045-11053. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9333 mL	19.6665 mL	39.3329 mL	98.3323 mL
	5 mM	0.7867 mL	3.9333 mL	7.8666 mL	19.6665 mL
	10 mM	0.3933 mL	1.9666 mL	3.9333 mL	9.8332 mL
	15 mM	0.2622 mL	1.3111 mL	2.6222 mL	6.5555 mL
	20 mM	0.1967 mL	0.9833 mL	1.9666 mL	4.9166 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Rubiadin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Ferroptosis Compound Library

Phenols Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Quinones Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

NF-κB アイソフォーム固有の製品をすべて表示

Parasite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Rubiadin 関連分類